clinical trial · NCT07635290
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer
West China Hospital·phase2·active not recruiting·n = 26
Previously Treated, AdvancedBiliary Tract CancersAnlotinib + CadonilimabPULSAR
brief summary
This study aims to evaluate the safety and preliminary efficacy of anlotinib combined with cadonilimab and PULSAR in previously treated advanced unresectable or netastatic biliary tract cancer.
started
Jun 3, 2026
primary completion
Jun 30, 2027
completion
Jun 30, 2028
last updated
Jun 9, 2026
official title
A Phase II Clinical Trial of Anlotinib Combined With Cadonilimab and PULSAR in Previously Treated Advanced Unresectable or Metastatic Biliary Tract Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol